Kaman Reports 2021 First Quarter Results
Kaman Corp. (NYSE:KAMN) today reported financial results for the first fiscal quarter ended April 2, 2021.
|
|
|
|
|
|
|
|
||||||
|
Table 1. Summary of Financial Results (unaudited) |
|
|
|
|
|
|||||||
|
In thousands except per share amounts |
For the Three Months Ended |
|
||||||||||
|
|
April 2,
|
|
April 3,
|
|
Change |
|
||||||
|
|
|
|
|
|
|
|
||||||
|
Net sales from continuing operations |
$ |
171,616 |
|
|
$ |
207,322 |
|
|
$ |
(35,706 |
) |
|
|
|
|
|
|
|
|
|
||||||
|
Operating income from continuing operations: |
|
|
|
|
|
|
||||||
|
Operating income (loss) from continuing operations |
$ |
5,613 |
|
|
$ |
(4,422 |
) |
|
$ |
10,035 |
|
|
|
% of sales |
3.3 |
% |
|
(2.1 |
)% |
|
5.4 |
% |
|
|||
|
Adjustments |
$ |
2,291 |
|
|
$ |
21,117 |
|
|
$ |
(18,826 |
) |
|
|
Adjusted operating income from continuing operations* |
$ |
7,904 |
|
|
$ |
16,695 |
|
|
$ |
(8,791 |
) |
|
|
% of sales |
4.6 |
% |
|
8.1 |
% |
|
(3.5 |
)% |
|
|||
|
|
|
|
|
|
|
|
||||||
|
Adjusted EBITDA from continuing operations*: |
|
|
|
|
|
|
||||||
|
Earnings (loss) from continuing operations |
$ |
7,984 |
|
|
$ |
(407 |
) |
|
$ |
8,391 |
|
|
|
Adjustments |
9,129 |
|
|
26,611 |
|
|
(17,482 |
) |
|
|||
|
Adjusted EBITDA from continuing operations* |
$ |
17,113 |
|
|
$ |
26,204 |
|
|
$ |
(9,091 |
) |
|
|
% of sales |
10.0 |
% |
|
12.6 |
% |
|
(2.6 |
)% |
|
|||
|
|
|
|
|
|
|
|
||||||
|
Earnings per share from continuing operations: |
|
|
|
|
|
|
||||||
|
Diluted earnings per share from continuing operations |
$ |
0.29 |
|
|
$ |
(0.01 |
) |
|
$ |
0.30 |
|
|
|
Adjustments |
— |
|
|
0.49 |
|
|
(0.49 |
) |
|
|||
|
Adjusted diluted earnings per share from continuing operations* |
$ |
0.29 |
|
|
$ |
0.48 |
|
|
$ |
(0.19 |
) |
|
|
|
|
|
|
|
|
|
Ian K. Walsh, Chairman, President and Chief Executive Officer, commented, “We begin the year with a solid quarter and confidence in our end-market recovery seeing significant sequential improvements in our Medical and Industrial end markets with strong order rates for these products. Sales for our Defense and Commercial, Business and General Aviation products declined both year-over-year and sequentially due to lower JPF volume and the impact of COVID-19, respectively. Looking to the remainder of the year, our JPF program remains on track and we anticipate a significant ramp up in sales for our Commercial, Business and General Aviation products in the second half of the year and are encouraged by increased air traffic and vaccination rates in the United States."
"Our cost control efforts carried forward into the first quarter where we achieved Adjusted EBITDA* margin of
"New product development remains an important part of our future growth and we have made significant progress on a number of these initiatives, including the opening of our first production cell for highly engineered products utilizing our proprietary Titanium Diffusion Hardening process and the successful test flight for our new unmanned K-MAX TITAN TM system. This test flight is a significant milestone in enabling us to meet the future unmanned logistics requirements of our commercial and defense customers. As we look to the remainder of the year, we anticipate sequential organic growth and continued progress on our new product development efforts and our strategic acquisitions priorities."
Management's Commentary on First Quarter Results:
Net sales for the quarter decreased
Sales for our Defense products decreased
Sales for our Commercial, Business and General Aviation products decreased